Ansell Limited · ASX:ANN
Ansell — UBS Global Life Science Conference September 2005
19 slides from Ansell's conference presentation, Sep 27, 2005
Slide 1: Ansell Limited
Ansell Limited UBS Global Life Science Conference September 2005 Doug Tough – Chief Executive Officer Rustom Jilla – Chief Financial Officer
Slide 2: Agenda and Forward-Looking Statements
1. Overview —Doug Tough 2. Results —Rustom Jilla 3. Strategic Focus —Doug Tough FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended, and information that is based on management’s beliefs as well as assu
Slide 3: Overview
Overview Doug Tough
Slide 4: ENCORE cot
ENCORE cot TE ORBWL PERSIE, Ans
Slide 5: Who is Ansell?
Who is Ansell? A 100+ year old company A world leader in healthcare barrier protection products and services An Australian listed Company (ASX: ANN) with ADSs on US (NASDAQ: ANSL) Market capitalization ~US$1.3 billion Sales of ~US$820 million and approximately 11,000 employees Statutory HQ in Austra
Slide 6: Life is a risky business
Life. is a risky business… Infections, Contamination, Viruses & Bacteria, Toxins, Injuries 4.7m work related injuries & illnesses in USA in 2002. Cost $170b Over 2 million people get infections in US hospitals each year; costing $5b Only 25% of sexually active people use condoms. Lifetime medical co
Slide 7: A Global Leader
A Global Leader Estimated global market size and positions Surgical Gloves Market: US$0.6B 2004 #2 Ansell 23% Occupational Gloves (Synthetics) Market: US$2.1B 2004 #1 Ansell 20% Exam Gloves (Excluding Occupational) Market: US$1.0B 2003 #2 Ansell 10% Consumer (Condoms) Market: US$0.9B 2003 #3 Ansell
Slide 8: Key Customers
Key Customers Companies: industrial, auto, chemicals, food etc. Hospitals/Medical Centres Retail: food stores, drug stores, convenience stores, mass merchandisers
Slide 9: Manufacturing
Manufacturing Facilities Outsource US$75 M Powdered Exam Vinyl Exam Low Volume Items Americas & UK Chemical Resistant General Purpose Specialty High spec knitted India & Sri Lanka Standard & Premium Surgical Condoms Powder Free Exam General Purpose Chemical Resistant Critical Environment Employees 8
Slide 10: Results
RESUIiS Rustom) Jilla
Slide 11: Ansell Regions
Ansell Regions – F’05 SALES ($M) = 823.9 15% Asia Pacific 122.5 Americas 395.3 Europe 306.1 37% 48% EBITA ($M) = 115.7 25% Asia Pacific 29.3 Americas 51.1 Europe 35.3 44% 31%
Slide 12: Successful Performance Trends
Successful Performance Trends US$M F’03 F’04 F’05 3 Year CAGR Sales 758.7 791.9 823.9 4% Professional: On 6 out of 7 US GPO’s Growth In European Branded Surgical Market Consumer: New Exciting Retail Offerings – 4 Play, Vibe Product Improvements – Ultra Thin Condom Public Sector Tender Contracts Occu
Slide 13: Successful Performance Trends Cont.
Successful Performance Trends Cont. US$M F’03 F’04 F’05 3 Year CAGR Segment EBITA 93.6 104.1 115.7 11% EBITA/Sales Margin 12.3% 13.1% 14.0% 7% Professional: Trend from Powdered Surgical/Exam Gloves to Powder Free and Synthetic Production moved from US to Asia, Asian outsourcing Consumer: New Product
Slide 14: Successful Performance Trends Cont.
Successful Performance Trends Cont. US$M 3 Year F’03 F’04 F’05 CAGR Attributable Profit – Pre SPT 29.3 50.4 68.8 53% – Post SPT 29.3 50.4 7.9 Free Cash Flow 67.5 76.3 93.8 18% Working Capital 167.5 168.6 168.8 0.4% Gearing (Net Debt/Net Debt & Equity) 18.1% 12.8% 19.6% 4% Healthcare ROA (Excluding S
Slide 15: Delivering Total Shareholder Return
Delivering Total Shareholder Return EPS (Pre SPT write-down) A26.7¢ A39.1¢ A54.5¢ ROE (Pre SPT write-down) 5.6% 8.8% 12.6% Dividends A11¢ A13¢ A17¢ 10.5 10 9.5 9 8.5 8 7.5 7 6.5 6 5.5 5 4.5 4 3.5 3 2.5 1 July 02 31 Dec 02 30 June 03 31 Dec 03 30 June 04 31 Dec 04 30 June 05 $6.58 $3.70 3,228 F’03 TS
Slide 16: Strategic Focus
at Strategic Focus Dovig hough
Slide 17: Strategic Evolution
Strategic Evolution From meeting multi-year Segment EBITA commitments to advancing Ansell Growth Strategy for F’06 and Beyond Methodology: F’05 Base Organic Growth Geographic Focus Technology Bolt on Acquisitions Strategic Initiatives
Slide 18: Key Messages
Key Messages A Global Leader Strong Market Positions Geographic & Product Diversification A Solid Record of Delivering Profit Growth, Shareholder Value and High ROA Established Platform for Future Growth among compelling opportunities - Organic - Geographical - External
Slide 19: Signature
ANSELL LIMITED SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ANSELL LIMITED (Registrant) By: /s/ DAVID M. GRAHAM Name: DAVID M. GRAHAM Title: GENERAL
Ansell — UBS Global Life Science Conference September 2005 on 6ix